BlossomHill Therapeutics

aid: blossomhill-therapeutics
name: BlossomHill Therapeutics
description: 'BlossomHill Therapeutics is a privately held, clinical-stage biopharmaceutical company headquartered in San
  Diego, California, founded in 2020 by drug designer J. Jean Cui, Ph.D. and biotech operator Y. Peter Li, Ph.D., M.B.A. It
  develops intelligently designed small-molecule medicines for oncology and autoimmune disease, led by BH-30643, a first-in-class
  macrocyclic non-covalent mutant-selective OMNI-EGFR inhibitor for EGFR- and HER2-mutated non-small cell lung cancer, and
  BH-30236, a macrocyclic CLK inhibitor for relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic
  syndrome. The company is a drug discovery business, not a software vendor: it publishes no public API, SDK, developer portal
  or machine-readable specification.'
image: https://bhtherapeutics.com/wp-content/uploads/logo-stacked.svg
url: https://raw.githubusercontent.com/api-evangelist/blossomhill-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-07'
modified: '2026-08-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Drug Discovery
- Clinical Trials
- Life Sciences
- Precision Medicine
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/blossomhill-therapeutics-domain-security.yml
- type: Website
  url: https://bhtherapeutics.com/
- type: About
  url: https://bhtherapeutics.com/about-us/
- type: Pipeline
  url: https://bhtherapeutics.com/pipeline/
- type: Investors
  url: https://bhtherapeutics.com/investors/
- type: Blog
  url: https://bhtherapeutics.com/news/
- type: PressReleases
  url: https://bhtherapeutics.com/press-releases/
- type: BlogRSS
  url: https://bhtherapeutics.com/feed/
- type: Contact
  url: https://bhtherapeutics.com/contact/
- type: Careers
  url: https://bhtherapeutics.com/careers/
- type: TermsOfService
  url: https://bhtherapeutics.com/terms-of-service/
- type: PrivacyPolicy
  url: https://bhtherapeutics.com/privacy-policy/
- type: CookiePolicy
  url: https://bhtherapeutics.com/cookie-policy/
- type: LLMsTxt
  url: llms/blossomhill-therapeutics-llms.txt
  name: llms.txt (published, but every link points at staging)
  description: 'Harvested verbatim from https://bhtherapeutics.com/llms.txt (HTTP 200, generated by All in One SEO 4.9.10).
    Recorded as-published and unusable as an agent surface: every one of the 33 URLs it advertises — the sitemap, all 13 pages
    and all 17 team profiles — points at the Kinsta build/staging host stg-blossomhill-build.kinsta.cloud, which answers HTTP
    401 to anonymous requests, rather than at the production host bhtherapeutics.com. Probed 2026-08-07.'
- type: LinkedIn
  url: https://www.linkedin.com/company/blossomhill-therapeutics-inc
- type: Twitter
  url: https://twitter.com/bhtherapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/blossomhill-therapeutics_stock/
x-enrichment:
  date: '2026-08-07'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: BlossomHill is a clinical-stage oncology drug-discovery company with no developer site and no API product; every
    OpenAPI, GraphQL, MCP and agent-card path on bhtherapeutics.com returns 404, api./docs./developer.bhtherapeutics.com do
    not resolve, and the only machine-readable surface on the domain is the default WordPress /wp-json REST root its marketing
    CMS exposes.
  evidence:
  - url: https://bhtherapeutics.com/openapi.json
    status: 404
  - url: https://bhtherapeutics.com/.well-known/agent-card.json
    status: 404
  - url: https://bhtherapeutics.com/graphql
    status: 404
  - url: https://bhtherapeutics.com/wp-json/
    status: 200
  - url: https://stg-blossomhill-build.kinsta.cloud/
    status: 401
  checked: '2026-08-07'